• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Scottish Medicines Consortium (SMC) - Articles and news items

Crizotinib lung cancer price drop

NICE recommends Pfizer’s lung cancer drug after price drop

Industry news / 18 August 2016 / The National Institute for Health and Care Excellence (NICE)

When initially reviewed, the committee concluded that the drug was too expensive compared to the current standard of care. Pfizer submitted further evidence, including a new patient access scheme that provided the drug at a lower price alongside revised analyses, which the committee then concluded could now be considered value for money on the NHS…

SMC u turn lifeline

SMC ‘U-turn’ offers lifeline to Scottish skin cancer patients

Industry news / 8 August 2016 / Bristol-Myers Squibb

The SMC initially refused access to nivolumab for Scottish patients, having taken a different view to the National Institute for Health and Care Excellence (NICE), which approved it to treat patients in England and Wales. However, following a review of additional evidence, the SMC decision has been reversed, bringing access in Scotland on par with the rest of the UK…

smc

SMC accepts five new medicines for use in NHS Scotland

Industry news / 11 July 2016 / Victoria White, Digital Content Producer

The SMC has accepted five new medicines for routine use in NHS Scotland including lung cancer treatments nivolumab and crizotinib…

cystic fibrosis

SMC says ‘no’ to Kalydeco and Orkambi in cystic fibrosis

Industry news / 9 May 2016 / Victoria White, Digital Content Producer

While the SMC has rejected Kalydeco and Orkambi, The Cystic Fibrosis Trust has put forward a solution for the drugs to be considered by the NMF…

smc

SMC accepts three new medicines for use by NHS Scotland; rejects two

Industry news / 12 April 2016 / Victoria White, Digital Content Producer

Everolimus for advanced breast cancer, savuconazole for invasive aspergillosis and mucormycosis, and camellia sinensis for genital warts were all accepted…

smc

SMC accepts three medicines for use in NHS Scotland; rejects two

Industry news / 7 March 2016 / Victoria White

Eisai’s Halaven (Eribulin) for advanced breast cancer, Novartis’ Entresto (sacubitril/valsartan) for chronic heart failure and Astellas’ Xtandi (enzalutamide) for prostate cancer were all accepted…

smc

SMC accepts five new medicines; rejects eculizumab

Industry news / 9 February 2016 / Victoria White

The committee was unable to accept eculizumab as it was “not considered to represent an effective use of NHS Scotland’s resources”…

cytos

SMC accepts Keytruda as a treatment option for advanced melanoma

Industry news / 10 November 2015 / Victoria White

The SMC also announced positive recommendations for Roche’s Avastin (bevacizumab) and Daiichi Sankyo’s Lixiana (edoxaban)…

smc

SMC accepts six new medicines for use by NHS Scotland

Industry news / 12 October 2015 / Victoria White

The medicines accepted by the SMC include Herceptin for stomach cancer, radium 223 (Xofigo) and abiraterone (Zytiga) for prostate cancer, and nintedanib (Ofev) for idiopathic pulmonary fibrosis

Regorafenib

SMC accepts sorafenib for use in Scotland

Industry news / 13 July 2015 / Victoria White

The SMC has announced that sorafenib has been accepted for use within NHS Scotland for the treatment of patients with thyroid carcinoma…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +